Claims for Patent: 6,644,320

Summary for Patent: 6,644,320

Title:	Treatment of hepatitis C using hyperthermia
Abstract:	The invention provides a method of treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient\'s viral load of HCV.
Inventor(s):	Groth; Karl Emil (St. Paul, MN), Kelly; Theodore Charles (Minnetonka, MN), Westerbeck; Todd L. (Burnsville, MN), Blick; Gary (Stamford, CT)
Assignee:	First Circle Medical, Inc. (Minneapolis, MN)
Application Number:	09/951,830
Patent Claims:	1. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 2. The method of claim 1, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 3. The method of claim 1, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 4. The method of claim 1, wherein the temperature of the patient's liver is raised and returned to normal one time. 5. The method of claim 1, wherein the temperature of the patient's liver is raised and returned to normal two or more times. 6. The method of claim 1, wherein the patient's viral load of HCV is determined at least once before the temperature of the patient's liver has been raised said at least one time. 7. The method of claim 1, wherein the patient's viral load of HCV is determined at least two different times after the temperature of the patient's liver has been raised and returned to normal said at least one time. 8. The method of claim 1, wherein the patient's viral load of HCV is reduced by 50 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 9. The method of claim 1, wherein the patient's viral load of HCV is reduced by 75 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 10. The method of claim 1, wherein the patient's viral load of HCV is reduced by 90 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 11. The method of claim 1, wherein the patient's viral load of HCV is reduced by 95 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 12. The method of claim 1, further comprising treating the patient with a pharmaceutical indicated for hepatitis C. 13. The method of claim 12, wherein the patient is treated with a single pharmaceutical indicated for treating hepatitis C. 14. The method of claim 12, wherein the patient is treated with two or more pharmaceuticals indicated for treating hepatitis C. 15. The method of claim 12, wherein the pharmaceutical is administered before raising the temperature of the patient's liver said at least one time. 16. The method of claim 12, wherein the pharmaceutical is administered while the temperature of the patient's liver is raised. 17. The method of claim 12, wherein the pharmaceutical is administered after the temperature of the patient's liver has been raised and returned to normal said at least one time. 18. The method of claim 12, wherein the pharmaceutical is administered: (i) before raising the temperature of the patient's liver said at least one time; (ii) while the temperature of the patient's liver is raised; (iii) after the temperature of the patient's liver has been raised and returned to normal said at least one time; or (iv) combinations thereof. 19. The method of claim 12, wherein the pharmaceutical is administered before raising the temperature of the patient's liver said at least one time, while the temperature of the patient's liver is raised, and after the temperature of the patient's liver has been raised and returned to normal said at least one time. 20. The method of claim 12, wherein the pharmaceutical is selected from interferons, protease inhibitors, cytokines, or any combination of antiviral drugs. 21. The method of claim 12, wherein the pharmaceutical is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, histamine dihydrochioride, thymalfasin, zidovudine, didanosine, zalcitabine, stavudine, abacavar, nevirapine, delaviridine, efavirenz, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, or combinations thereof. 22. The method of claim 12, wherein the pharmaceutical is selected from an interferon, ribavirin, or lamivudine. 23. The method of claim 12, wherein the pharmaceutical is an alpha interferon. 24. The method of claim 1, wherein the patient has an acute HCV infection. 25. The method of claim 1, wherein the patient has a chronic HCV infection. 26. The method of claim 1, wherein the patient is co-infected with a pathogen. 27. The method of claim 26, wherein the pathogen is a virus. 28. The method of claim 27, wherein the virus is a heat labile virus. 29. The method of claim 28, wherein the heat labile virus is selected from herpesviruses, hepadnaviruses, togaviruses, flaviviruses, coronaviruses, rhabdoviruses, filoviruses, paramyxoviruses, othomyxoviruses, bunyaviruses, arenaviruses, or retroviruses. 30. The method of claim 28, wherein the heat labile virus is selected from HIV, hepatitis B virus, Ebstein-Barr virus, cytomegalovirus, or varicella-zoster virus. 31. The method of claim 26, wherein the pathogen is a spirochete or bacterium. 32. The method of claim 31, wherein the pathogen is a spirochete selected from the genus treponema, borrelia, or leptospira. 33. The method of claim 31, wherein the pathogen is a spirochete selected from Treponema pallidum, Treponema pertenue, Treponema carateum, Treponema pallidum endemicum, Borrelia burgdorferi, Borrelia hermsii, or Leptospira interrogans. 34. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a branched DNA signal amplification test three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 35. The method of claim 34, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 36. The method of claim 34, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 37. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 38. The method of claim 37, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 39. The method of claim 37, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 40. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 41. The method of claim 40, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 42. The method of claim 40, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 43. The method of claim 40, wherein the patient's viral load of HCV is reduced by 50 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 44. The method of claim 40, wherein the patient's viral load of HCV is reduced by 75 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 45. The method of claim 40, wherein the patient's viral load of HCV is reduced by 90 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 46. The method of claim 40, wherein the patient's viral load of HCV is reduced by 95 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 47. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a branched DNA signal amplification test one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 48. The method of claim 47, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 49. The method of claim 47, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 50. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 51. The method of claim 50, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 52. The method of claim 50, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 53. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 54. The method of claim 53, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 55. The method of claim 53, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 56. The method of claim 53, wherein the temperature of the patient's liver is raised and returned to normal one time. 57. The method of claim 53, wherein the temperature of the patient's liver is raised and returned to normal two or more times. 58. The method of claim 53, wherein the patient's viral load of HCV is determined at least once before the temperature of the patient's liver has been raised said at least one time. 59. The method of claim 53, wherein the patient's viral load of HCV is determined at least two different times after the temperature of the patient's liver has been raised and returned to normal said at least one time. 60. The method of claim 53, wherein the patient's viral load of HCV is reduced by 50 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 61. The method of claim 53, wherein the patient's viral load of HCV is reduced by 75 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 62. The method of claim 53, wherein the patient's viral load of HCV is reduced by 90 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 63. The method of claim 53, wherein the patient's viral load of HCV is reduced by 95 percent or more three months after the temperature of the patient's liver has been raised and returned to normal said at least one time. 64. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a branched DNA signal amplification test three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 65. The method of claim 64, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 66. The method of claim 64, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 67. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test three months after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 68. The method of claim 67, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 69. The method of claim 67, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 70. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV by 30 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 71. The method of claim 70, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 72. The method of claim 70, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 73. The method of claim 70, wherein the patient's viral load of HCV is reduced by 50 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 74. The method of claim 70, wherein the patient's viral load of HCV is reduced by 75 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 75. The method of claim 70, wherein the patient's viral load of HCV is reduced by 90 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 76. The method of claim 70, wherein the patient's viral load of HCV is reduced by 95 percent or more one month after the temperature of the patient's liver has been raised and returned to normal said at least one time. 77. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a branched DNA signal amplification test one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 78. The method of claim 77, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 79. The method of claim 77, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 80. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce the patient's viral load of HCV to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test one month after the temperature of the patient's liver has been raised and returned to normal said at least one time, wherein the patient is co-infected with HIV, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 81. The method of claim 77, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia. 82. The method of claim 80, wherein the temperature of the patient's liver is raised by intraperitoneal hyperthermia. 83. A method for treating a patient infected with hepatitis C virus (HCV) comprising raising the temperature of the patient's liver and then returning the temperature of the patient's liver to normal at least one time, wherein the temperature of the patient's liver is raised to a temperature range and a duration sufficient to reduce or eliminate the patient's viral load of HCV, further comprising treating the patient with a pharmaceutical indicated for hepatitis C, wherein the pharmaceutical is administered before raising the temperature of the patient's liver said at least one time, while the temperature of the patient's liver is raised, and after the temperature of the patient's liver has been raised and returned to normal said at least one time, and wherein the patient's viral load of HCV is determined at least once after the temperature of the patient's liver has been raised and returned to normal said at least one time. 84. The method of claim 83, wherein the temperature of the patient's liver is raised by local, regional, or intraperitoneal hyperthermia.

Details for Patent 6,644,320

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2039-02-26